Portal Vein Occlusion Prior to Extensive Resection in Colorectal Liver Metastasis: A Necessity Rather than an Option! by unknown
EDITORIAL
Portal Vein Occlusion Prior to Extensive Resection in Colorectal
Liver Metastasis: A Necessity Rather than an Option!
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Preoperative portal vein occlusion (PVO) of one liver
lobe is regularly used for inducing liver hypertrophy of the
contralateral lobe to prevent postoperative liver failure in
patients with an anticipated insufficient future liver rem-
nant (FLR) following resection.1 A similar rate of
hypertrophy of the liver parenchyma with preserved portal
flow can be obtained either by percutaneous portal embo-
lization using several agents or by portal vein ligation.2
This strategy of preoperatively manipulating the liver
volume has been acclaimed as a major step in liver surgery,
paving the way for extensive resection for initially unre-
sectable tumors.3
It has been clearly shown that chemotherapy of colo-
rectal liver metastases (CRLM) can provide significant
downstaging of liver disease enabling curative rescue
resection and translating into an improved long-term sur-
vival.3 Over the last decade, both PVO and chemotherapy
have dramatically widened the scope of surgical resection
of CRLM. Several institutions involved in the surgical
treatment of CRLM have claimed that preoperative PVO
has increased the number of candidates for complete tumor
resection.3–5 The hypertrophy of the FLR allows the safety
of major resection.
In the present issue, the article by Pamecha et al. tends
to dampen the early enthusiasm regarding PVO for
CLRM.6 This well-written article, which compares the
surgical outcomes of two groups of patients operated for
CRLM with or without portal vein embolization (PVE),
highlights the unfavorable effects of PVE. Firstly, one-third
of the patients were nonoperable after PVE because of
rapid progression of disease, and secondly the long-term
survival for patients resected after PVE was less favorable
than for the group who underwent immediate surgery.
A legitimate concern is whether the stimulus for liver
regeneration induced by PVO might enhance tumor growth.
As reported in a recent review of this journal, experimental
studies have shown that hepatectomy or portal ligation in
rats induced tumor growth and in some clinical studies, after
PVO, the growth rate of liver metastasis seems to be more
rapid than that of the liver parenchyma including a higher
proliferative activity of intrahepatic metastasis possibly
induced by hyper arterializations.7
Although these studies clearly demonstrate that tumor
progression after PVO is possible, we believe that it is not
yet time to consider a restriction of preoperative modula-
tion of the liver parenchyma by PVO. Percutaneous
embolization is a safe procedure that could reduce intra-
hepatic recurrence rate after right hepatectomy for unilobar
CRLM.8 Several series have shown that in patients with
extensive CRLM who would otherwise be unresectable,
PVO followed by surgery offers a significant benefit with a
5-year survival up to 40%.5,8–11 In these studies the evi-
dence of direct stimulation of tumor growth by PVE is
circumstantial, and the rate of unresectability after PVE
due to intrahepatic and/or extrahepatic tumor progression is
regularly around 25%, which is not very different from the
results of Pamecha et al.6
The main problem raised by this article is the indication
of PVO and its association with chemotherapy before a
major liver resection. The indication of PVO should
depend on several factors including the extent and expected
difficulties of resection, the status of nontumorous liver
parenchyma, and the exact quantification of sufficient
minimal functional hepatic volume. We have clearly
demonstrated that a right hepatectomy, which is the main
procedure performed after PVO, can be safely performed in
patients with normal parenchyma.12 Therefore, except in
patients with a FLR less than 25% of the total volume and
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those requiring an associated procedure in the FLR, there is
no indication of preoperative PVO. The same prospective
study has shown that PVO is beneficial in patients with a
diseased parenchyma. As a matter of fact, nowadays,
nearly all patients operated for CRLM had received pre-
operative chemotherapy that could induce parenchymal
changes altering the regenerative capacity of the FLR.
Although the impact of these various changes on the out-
come of the liver function remains debatable, there are
some arguments to consider PVO in patients who received
numerous cycles of chemotherapy.13 This approach, which
requires further study, could be established according to
results of preoperative biopsy of the nontumorous liver.
We agree with Pamecha et al. that in patients with
bilobar CRLM considered for a right hepatectomy, the
presence of tumors in the left liver requires specific con-
sideration. Firstly, chemotherapy after PVE should not be
interrupted. There are some data suggesting that chemo-
therapy does not impair hypertrophy of the left liver after
right PVO and may be continued after completion of the
PVO.14 Another possibility is to ablate small CRLM in the
FLR by percutaneous radiofrequency before PVO. In cases
of large CRLM in the FLR, a two-stage surgical procedure
can be recommended.9 In the first stage, all visible metas-
tases in the left hemiliver are cleared in association with
right portal ligation, and in the second stage a right or
extended right hemihepatectomy is performed after use of
concomitant chemotherapy, excluding bevacizumab.
In summary, the benefits of a potential cure after a
complete surgical resection after PVO in extensive CRLM
outweigh the risks of tumor progression since these patients
are otherwise unresectable. PVO should be strictly limited
to those with a significant risk of postoperative liver
insufficiency. Hence, rather than an optional procedure, it
is a compulsion in this group of patients to facilitate a
possible curative resection. Encouraging long-term sur-
vival after complete resections in patients who are
‘‘unresectable,’’ coupled with the ever-expanding horizons
of chemotherapy, clearly tilt the balance in favor of pre-
operative liver volume modulation. Future studies should
focus on strategies to reduce the risk of disease progression
after PVO. Tumor progression during chemotherapy is
clearly a negative prognostic factor that should help filter
the likely beneficiaries. A step further in patient selection
may be to ascertain the rate of tumor necrosis induced by
chemotherapy.15 These strategies may enable a more
selective approach in offering PVO and subsequent surgery
to those who are more likely to benefit from it.
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